Greg Freiherr, Industry Consultant
Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Sponsored Content | Blog | Greg Freiherr, Industry Consultant | PET Imaging | December 11, 2018

Digital Technology Pushes PET In New and Old Directions

A 90-second brain acquisition with FDG radiotracer — comparison of digital (Vereos, left, 1 mm) and conventional (Gemini TF, 4 mm) images.

A 90-second brain acquisition with FDG radiotracer — comparison of digital (Vereos, left, 1 mm) and conventional (Gemini TF, 4 mm) images.

Digital technology is opening remarkable opportunities for clinical positron emission tomography (PET) about which research is only beginning to hint.

“Twenty years ago we were excited that we could see a lesion. Now we want to understand its underlying biologic heterogeneity,” said Michael Knopp, M.D., a radiology professor at Ohio State University whose research with Philips’ digital PET/CT, called Vereos, is exploring applications within and beyond traditional clinical areas.

The digital technology underlying Vereos can provide the details that may escape analog systems, said Piotr Maniawski, director of clinical science for nuclear medicine at Philips Healthcare. Visualization using 4 mm cubes, which are typically delivered by analog systems, makes small lesions look spherical, he said. The very small voxels in digital images better visualize shapes and texture.

“Seeing if the texture is changing helps characterize the lesion,” said the Philips clinical director. The metabolism inside the lesion, he said, may be much different, depending on the location.

In a paper published May 2017 in the journal Contrast Media and Molecular Imaging, Knopp, who is the Novartis chair of Imaging Research at Ohio State University, and colleagues at Ohio State summarized how digital PET enables advanced functional tumor imaging.

 

A Digital Twist

Much like radiography began, PET started as an analog modality. Instead of film, PET relied on photomultiplier tubes (PMTs). In analog systems, light generated by a single scintillating crystal is channeled to multiple PMTs. In Vereos, light generated by a single scintillating crystal is channeled to its own detector.

Vereos’ digital detection is built on digital photon counting (DPC) technology, whereby crystals and sensors are coupled “one-to-one,” said Maniawski, who has worked with Knopp and others to assess the clinical capabilities conferred by Vereos’ digital technology. Light flashes produced by specific crystals are channeled directly to individual digital sensors. In stark contrast to analog technology, which accumulates signals from light flashes in analog detectors until reaching trigger points, “there is no light sharing,” Maniawski said. “The moment the detector registers this light, we know precisely which crystal produced it.”

Reconstruction algorithms onboard Vereos mathematically reconstruct digital PET into detailed images. These appear “more rich and precise” than those made using analog-based PET systems, Knopp said, due to the increased density of the data. The OSU researcher likened the benefit of data density to the improvement of smartphone images as those pictures gain more data density.

“When you pull up Google maps, the picture might look fuzzy at first and then as the data come in, it will look sharp and brilliant,” Knopp said. “This happens because the data density changes.”

Maniawski explained that voxels in Vereos images are densified with data collected by the 23,000 solid-state sensors from individual scintillation events. This added data density allows Vereos to package data into voxel volumes of 2 mm — or even 1 mm — cubes. This data density gives shape and texture to structures in the images.

 

Bringing Together Old and New

The game-changing appearance of Vereos’ images can be challenging, Knopp noted.

Because digital images show more detail, they may show lesions and features that might not be seen with analog technology. When comparing current digital images to past analog ones, the question arises: Were lesions now visible not seen previously because the technology could not see them? Or have they just recently occurred?

The answers to these questions can directly impact the management of patients being monitored for disease recurrence.

To deal with this incompatibility, Philips offers a feature in Vereos that reconstructs digital data as if they were acquired on an analog system. This is done with reconstruction algorithms, Maniawski said. These algorithms harmonize the digital data.

Vereos users who choose this option “end up with two images from the same data — a conventional looking image and a digital one,” Maniawski said.

Vereos can create a still picture and visualize changes over time. In the mid- to late-1980s, early developers of PET often acquired data dynamically. Serial acquisitions came into vogue when PET/CT imaging entered the mainstream. But dynamic imaging, similar to short video clips, can provide clinical information not found in static images.

Editor’s Note: This is the fifth in a series of blogs on the advances of digital PET/CT. The first is entitled How Digital PET/CT Can Improve Clinical Care; the second Why – And How – Digital PET Is Better Than Analog; the third Digital PET Balances Scan Time and Resolution; the fourth What Precision Means To PET

 

Related Content:

SPECIAL SUPPLEMENT: Examining the Value of Digital PET/CT

Related Content

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare

News | Nuclear Imaging | January 27, 2020
January 27, 2020 — According to the new market research report "...
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

News | Nuclear Imaging | December 26, 2019
December 26, 2019 — The Feinstein Institutes for Medical R...
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

62-year-old woman with pure ground-glass nodules (GGN). PET/CT fusion image shows pure GGN with tumor maximum standardized uptake value of 2.8 (circle).

News | PET-CT | November 15, 2019
November 15, 2019 — According to an article published ahead-of-print in the...
GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...
University of Alabama at Birmingham Leading Production of Theranostic Radioisotope

Image courtesy of the University of Alabama at Birmingham

News | Radiopharmaceuticals and Tracers | August 29, 2019
The University of Alabama at Birmingham, in conjunction with researchers at the University of Wisconsin and Argonne...